Davita Healthcare stock hits 52-week low at $114.81
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DaVita HealthCare Partners Inc (DVA)
DaVita HealthCare Partners Inc stock price live, this page displays NYSE DVA stock exchange data. View the DVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DaVita HealthCare Partners Inc real time stock price chart below.
What Is the DaVita HealthCare Partners Inc Stock Price Today?
The DaVita HealthCare Partners Inc stock price today is 120.10.
What Is the Stock Symbol for DaVita HealthCare Partners Inc?
The stock symbol for DaVita HealthCare Partners Inc is ""DVA.""
What Stock Exchange Does DaVita HealthCare Partners Inc Trade On?
DaVita HealthCare Partners Inc is listed and trades on the NYSE stock exchange.
Is DaVita HealthCare Partners Inc a Good Stock to Buy?
Determining whether DaVita HealthCare Partners Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVA quote. (ISIN: US23918K1088)
What Is the DaVita HealthCare Partners Inc Stock Price Today?
The DaVita HealthCare Partners Inc stock price today is 120.10.
What Is the Stock Symbol for DaVita HealthCare Partners Inc?
The stock symbol for DaVita HealthCare Partners Inc is ""DVA.""
What Stock Exchange Does DaVita HealthCare Partners Inc Trade On?
DaVita HealthCare Partners Inc is listed and trades on the NYSE stock exchange.
Is DaVita HealthCare Partners Inc a Good Stock to Buy?
Determining whether DaVita HealthCare Partners Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVA quote. (ISIN: US23918K1088)
Currency in USD
Fair Value
An estimate of a DaVita's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
119.89
122.16
52 wk Range
113.97
179.60
DVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a DaVita's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
119.89122.16
52 wk Range
113.97179.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DVA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a DaVita's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
144.50
Upside
+20.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- DaVita Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Davita Healthcare stock hits 52-week low at $114.81
- Investing.com
- DaVita Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - DaVita Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
DaVita HealthCare Partners Inc Company Profile
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DaVita HealthCare Partners Inc SWOT Analysis
Dialysis Dynamics | DaVita navigates volume challenges while maintaining financial resilience, beating earnings expectations despite headwinds in treatment growth |
Strategic Diversification | Explore DaVita's success in phosphate binders and international operations, offsetting core business pressures and opening avenues for expansion |
Reimbursement Outlook | CMS proposes a +1.9% rate update for 2026, providing stability to DaVita's revenue projections amid a complex healthcare reimbursement landscape |
Analyst Perspectives | Barclays Capital sets a $169 price target, while DaVita's conservative guidance approach may position the company for potential upside surprises |
DaVita HealthCare Partners Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of $2.95 beat estimates by 6.12%, revenue reached $3.38B vs $3.36B forecast; stock dipped 0.73% after hours
- US treatment volumes declined 1.1%; cyber incident incurred $13M in costs; elevated mortality rates potentially linked to COVID-19
- Full-year guidance maintained: adjusted operating income $2.01-2.16B, adjusted EPS $10.20-11.30
- CEO emphasized patient care and innovation; CFO expressed confidence in meeting long-term guidance
- Challenges include declining treatment volumes, cyber incident costs, and potential impact of proposed Medicare dialysis rate increase
Last Updated: 06/08/2025, 00:00
Read Full TranscriptCompare DVA to Peers and Sector
Metrics to compare | DVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 11.0x | −1.6x | −0.6x | |
PEG Ratio | 1.95 | 0.11 | 0.00 | |
Price/Book | −14.8x | 0.8x | 2.6x | |
Price / LTM Sales | 0.6x | 0.8x | 3.3x | |
Upside (Analyst Target) | 17.8% | 37.9% | 40.3% | |
Fair Value Upside | Unlock | 11.9% | 3.9% | Unlock |
Analyst Ratings
1 Buy
7 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 144.50
(+20.32% Upside)
Earnings
Latest Release
Oct 29, 2025
EPS / Forecast
2.51 / 3.23
Revenue / Forecast
3.42B / 3.44B
People Also Watch
FAQ
What Stock Exchange Does DaVita Trade On?
DaVita is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for DaVita?
The stock symbol for DaVita is "DVA."
What Is the DaVita (DVA) Afterhours Price Today? (Afterhours variable test: 119.98) Current Date: 27 Nov 2025
After hours price: 119.98. After hours price change (units): -0.12. Price change percentage: -0.10%
What Is the DaVita Market Cap?
As of today, DaVita market cap is 8.48B.
What Is DaVita's Earnings Per Share (TTM)?
The DaVita EPS (TTM) is 9.76.
When Is the Next DaVita Earnings Date?
DaVita will release its next earnings report on 17 Feb 2026.
From a Technical Analysis Perspective, Is DVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has DaVita Stock Split?
DaVita has split 3 times.
How Many Employees Does DaVita Have?
DaVita has 76000 employees.
What is the current trading status of DaVita (DVA)?
As of 27 Nov 2025, DaVita (DVA) is trading at a price of 120.10, with a previous close of 121.37. The stock has fluctuated within a day range of 119.89 to 122.16, while its 52-week range spans from 113.97 to 179.60.
What Is DaVita (DVA) Price Target According to Analysts?
The average 12-month price target for DaVita is USD144.5, with a high estimate of USD186 and a low estimate of USD126. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +20.32% Upside potential.
What Is the DVA After Hours Price?
DVA's last after hours stock price is 119.98, the stock has decreased by -0.12, or -0.10%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.